-
Učinkovitost kombiniranega zdravljenja hiperholesterolemije s statini in ezetimibom - prikaz rezultatov raziskave SI-SPECT = Effectiveness of combined statin plus ezetimibe treatment of hypercholesterolemia - presentation of SI-SPECT programme resultsFras, ZlatkoBackground. Despite the established effectiveness of statins, still many patients with dyslipidemia do not achieve recommended LDL cholesterol (LDL-C) goals. Contributing factors may be inadequate ... dosing, as well as increased potential for intolerance and adverse effects with combinations of available agents. Ezetimibe, the first member of a new class of selective cholesterol absorption inhibitors, is an effective and safe agent for lowering LDL-C and non HDL-C and it was previously shown that ezetimibe and statin combination therapy increased the percentage of patients who achieved their LDL-C treatment goal. Objectives. Treatment monitoring programme SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) was setup to evaluate thetotal as well as LDL blood cholesterol lowering in patients treated with ezetimibe co-administered to on-going statin therapy in daily clinical practice (S+E). It was also investigated whether and to what extent the targetlevels set by the participating doctors are achieved by the co-administration therapy. Subject and methods. 1,067 pts (52% males, age 60,2years, 42,9% with CHD, 32,0% diabetes mellitus, 96,5% with hypercholesterolemia, and 69,6% hypertension) were enrolled to initiate ezetimibe 10 mg plus continued their already prescribed statin. Baselin lipid levels were compared to those obtained at the 2nd visit (12 to 16 weeks after the initiation). Results. Significant positive changes were achieved in various lipid parameters due to "add-on" ezetimibe+statin combination therapy.Total and LDL cholesterol as well as triglycerides (TG) decreased significantly (by 25,3%, 31,4%, and 28,9% respectively, p=0.000 for all comparisons), while HDL increased by 1,0% (NS) during the study period. (Abstract truncated at 2000 characters(Vir: Slovenska kardiologija : znanstveno strokovna revija za področje srčno-žilne medicine. - ISSN 1581-8543 (Letn. 3, št. 1, 2006, str. 14-21)Vrsta gradiva - članek, sestavni delLeto - 2006Jezik - slovenskiCOBISS.SI-ID - 21311193
Avtor
Fras, Zlatko
Teme
Hypercholesterolemia |
Drug Therapy |
Drug Therapy, Combination |
Antilipemic Agents |
Lipoproteins, Ldl Cholesterol |
Coronary Disease |
Diabetes Mellitus |
Hypertension |
Cholesterol |
Blood |
Triglycerides |
Blood |
Hiperholesterolemija |
Koronarna bolezen |
Lipolitiki |
Lipoproteini, LDL, holesterol |
Zdravilo, terapija sestavljena |
Hipertenzija |
Holesterol |
Sladkorna bolezen |
Trigliceridi
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Fras, Zlatko | 11685 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.